Search Results - "Rajman, I."

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension by Hsiao, H‐L, Langenickel, TH, Petruck, J, Kode, K, Ayalasomayajula, S, Schuehly, U, Greeley, M, Pal, P, Zhou, W, Prescott, MF, Sunkara, G, Rajman, I

“…Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF…”
Get full text

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome by Krone, W, Hanefeld, M, Meyer, H-F, Jung, T, Bartlett, M, Yeh, C-M, Rajman, I, Prescott, M F, Dole, W P

“…Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension…”
Get full text

PK/PD modelling and simulations: utility in drug development by Rajman, Iris

“…Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation can be used as an ‘applied science’ tool to provide answers on efficacy and safety of new…”
Get full text

Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men by Rajman, I., Kendall, M.J., Cramb, R., Holder, R.L., Salih, M., Gammage, M.D.

“…There is an increasing interest in low density lipoprotein (LDL) subfractions since some of them are associated with a higher risk for coronary artery disease…”
Get full text

Particle size: the key to the atherogenic lipoprotein? by Rajman, I, Maxwell, S, Cramb, R, Kendall, M

“…Using different analytical methods, up to 12 low-density lipoprotein (LDL) subfractions can be separated. LDL particle size decreases with increasing density…”
Get more information

LDL particle size : an important drug target? by RAJMAN, I, EACHO, P. I, CHOWIENCZYK, P. J, RITTER, J. M

Get full text

Adverse change in low-density lipoprotein subfractions profile with oestrogen-only hormone replacement therapy by Rajman, I., Lip, G.Y.H., Cramb, R., Maxwell, S.R.J., Zarifis, J., Beevers, D.G., Kendall, M.J.

“…In a prospective longitudinal study in 17 women, we investigated the effects of surgical menopause and subsequent oestrogen-only hormone replacement therapy…”
Get full text

Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants by Kendall, M. J., Rajman, I., Maxwell, S. R.

Get full text

Sudden cardiac death and the potential role of beta-adrenoceptor-blocking drugs by Rajman, I., Kendall, M. J.

“…Sudden cardiac death is a major health problem in the industrially developed countries. The risk of sudden cardiac death may be reduced by early detection of…”
Get full text

Low-density lipoprotein subfraction profiles in chronic renal failure by RAJMAN, I, HARPER, L, MCPAKE, D, KENDALL, M. J, WHEELER, D. C

“…Small low-density lipoprotein (LDL) particle size, a newly recognized risk factor for cardiovascular disease in the general population, is frequently…”
Get full text

Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease by Thalamas, Claire, Rajman, Iris, Kulisevsky, Jaime, Lledó, Alberto, Mackie, Alison E, Blin, Olivier, Gillespie, Todd A, Seger, Mary, Rascol, Olivier

“…The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new…”
Get full text

Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation by McNeill, Karen L., Fontana, Luigi, Russell-Jones, David L., Rajman, Iris, Ritter, James M., Chowienczyk, Philip J.

“…OBJECTIVES The object of the present study is to determine whether native (n) low-density lipoprotein (LDL) isolated from men with type II diabetes and…”
Get full text

Evaluation of Methods for Improving Precision of Blood Pressure Measurements in Phase I Clinical Trials by Terra, Steven G., Blum, Robert A., Wei, Greg C., Lew, Robert A., Digenio, Andres G., Rajman, Iris, Kazierad, David J.

“…Small sample sizes are typically incorporated in early Phase I clinical studies, which may lead to insignificant changes in safety parameters such as blood…”
Get full text

LDL particle size: an important drug target? by Rajman, I., Eacho, Patrick I., Chowienczyk, P. J., Ritter, J. M.

Get full text

A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease by Kendall, MJ, Rajman, I

“…Celiprolol is a third-generation beta -adrenoceptor blocker with selective beta sub(1)-antagonist, partial beta sub(2)-agonist and mild alpha sub(2)-antagonist…”
Get full text

The oxidation hypothesis of atherosclerosis by Rajman, I, Kendall, M, Cramb, R

Get more information

Cardioprotective therapeutics : drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidant by KENDALL, M. J, RAJMAN, I, MAXWELL, S. R. J

Get full text

A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease by KENDALL, M. J, RAJMAN, I

“…Celiprolol is a third-generation beta-adrenoceptor blocker with selective beta 1-antagonist, partial beta 2-agonist and mild alpha 2-antagonist actions. It…”
Get full text

Enanthema fixum as side effect in the use of a combination of trimethoprim and sulfamethoxazole by Arifhodzić, F, Rajman, I, Petronijević, S, Ivković, B

“…Cases of fixed drug eruption due to trimethoprim-sulfamethoxazole combination are reported. In these cases the oral mucous membranes were affected. Fixed drug…”
Get more information